Trial Profile

A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 2 Study to Evaluate the Safety and Efficacy of CT1812 in Subjects With Mild to Moderate Alzheimer's Disease

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 29 Aug 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

11 Aug 2025 According to ClinicalTrials.gov by the U.S. National Institutes of Health, the primary endpoints have been replaced with 2 new safety endpoints.
29 Jul 2025 According to a Cognition Therapeutics media release, results from this Phase 2 COG0201 SHINE study of zervimesine in Alzheimers disease were presented at the Alzheimers Association International Conference (AAIC 2025).
16 Jul 2025 According to a Cognition Therapeutics media release, data from this trial will be presented at the Alzheimer's Association International Conference (AAIC).

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com